Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Details 詳細情報について

• CRID

  1361137044575582848

• DOI

  10.1093/annonc/mdx235

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419321660?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419321660?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/28/8/2002/24169595/mdx235.pdf

• Data Source

  • Crossref